800-799-2234
Office Locations
Mon - Fri 09:00 am - 05:00 pm
Michigan's #1
Mesothelioma Law Firm
We Have Won
Thousands of Cases
Trusted By
10,000+ Clients
Immediate Assistance 24/7

Phase I Study of OSI-930 and Erlotinib in Cancer Tumors

Phase I Study of OSI-930 and Erlotinib in Cancer Tumors

You are here:
Estimated reading time: < 1 min

Condition: Advanced Solid Tumors

NCT Number: NCT00603356
Estimated Enrollment: 60
Phases: Phase 1
Age Group: 18 Years and older   (Adult, Older Adult)
Gender: All
Study Type: Interventional
Study Results: No Results Available

Study Design Allocation: Allocation: No Results Available

Study ID Numbers: OSI-930-103
Study First Received: January 29, 2008
Last Updated: September 27, 2011
Estimated Primary Completion Date: April 2010
Completion Date: July 2010

Primary Outcome Measures: Determine the maximum tolerated dose (MTD), evaluate the pharmacokinetic profiles|Safety, evaluate pharmacodynamic relationships

Sponsors and Collaborators: Astellas Pharma Inc|OSI Pharmaceuticals
Funded By: Industry
Interventions: Drug: Drug: OSI-930 and erlotinib

Locations: H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

Website Link: https://ClinicalTrials.gov/show/NCT00603356

Was this article helpful?
Dislike 0
Call Now ButtonCALL NOW